Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12705542 | 0.83 | SMYD3 (0.39) | ALDH1A1HTTTSHRPOLBMAPT | |
| SCHEMBL13920580 | 0.82 | ALDH1A1 (0.37) | ALDH1A1HTTTSHRPOLBMAPT | |
| SCHEMBL3771260 | 0.80 | ALDH1A1 (0.40) | ALDH1A1TSHRPOLBSMYD3MEN1 | |
| SCHEMBL3644549 | 0.80 | ALDH1A1 (0.40) | ALDH1A1TSHRPOLBSMYD3MEN1 | |
| SCHEMBL12396230 | 0.80 | ALDH1A1 (0.40) | ALDH1A1TSHRPOLBSMYD3MEN1 | |
| SCHEMBL2159702 | 0.80 | ALDH1A1 (0.40) | ALDH1A1TSHRPOLBSMYD3MEN1 | |
| SCHEMBL8274289 | 0.80 | ALDH1A1 (0.40) | ALDH1A1TSHRPOLBSMYD3MEN1 | |
| SCHEMBL464766 | 0.72 | KMT2A (0.37) | ALDH1A1MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL464765 | 0.72 | KMT2A (0.37) | ALDH1A1MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL20113215 | 0.72 | KMT2A (0.37) | ALDH1A1MAPTMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985860-B2 | Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives | SCHERING CORPORATION (US) | 2011-07-26 | — | — | US | disclosed |
| US-20080045718-A1 | Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives | MERCK SHARP & DOHME CORP. | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045718-A1 | Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives | PDE4B, PDE4A, PDE3B | ALDH1A1 1147/4885HTT 4132/4885TSHR 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.